An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients

References

• Available from: https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf. Accessed 909, 2019.
   Google Scholar
• EMA Perampanel approval. https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa#authorisation-details-section. Accessed 909, 2019.
   Google Scholar
• Satlin A, Kramer LD, Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand. 2013;127:3–8. doi:10.1111/ane.2013.127.issue-s197
   Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures Randomized phase III study 304. Neurology. 2012;79(6):589–596. doi:10.1212/WNL.0b013e318263573522843280
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117–125. doi:10.1111/j.1528-1167.2012.03638.x22905857
   PubMed Web of Science ®Google Scholar
• Rosenfeld W, Conry J, Lagae L, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19(4):435–445. doi:10.1016/j.ejpn.2015.02.00825823975
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306 Adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–1415. doi:10.1212/WNL.0b013e318254473a22517103
   PubMed Web of Science ®Google Scholar
• Nishida T, Lee SK, Inoue Y, Saeki K, Ishikawa K, Kaneko S. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study. Acta Neurol Scand. 2018;137(4):392–399. doi:10.1111/ane.1288329250772
   PubMed Web of Science ®Google Scholar
• Villanueva V, Majid O, Nabangchang C, et al. Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with in adequately controlled partial-onset seizures. Epilepsy Res. 2016;127:126–134. doi:10.1016/j.eplepsyres.2016.08.02527595590
   PubMed Web of Science ®Google Scholar
• Meador KJ, Yang HC, Pina-Garza JE, Laurenza A, Kumar D, Wesnes KA. Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial. Epilepsia. 2016;57(2):243–251. doi:10.1111/epi.1327926724782
   PubMed Web of Science ®Google Scholar
• Lagae L, Villanueva V, Meador KJ, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016;57(7):1120–1129. doi:10.1111/epi.1341727221398
   PubMed Web of Science ®Google Scholar
• Pina-Garza JE, Lagae L, Villanueva V, et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav. 2018;83:50–58. doi:10.1016/j.yebeh.2018.03.02929653338
   PubMed Web of Science ®Google Scholar
• Takenaka O, Ferry J, Saeki K, Laurenza A. Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. Acta Neurol Scand. 2018;137(4):400–408. doi:10.1111/ane.1287429171002
   PubMed Web of Science ®Google Scholar
• Contin M, Bisulli F, Santucci M, et al. Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy. Epilepsia. 2018;59(7):E103–E8. doi:10.1111/epi.1444629897632
   PubMed Web of Science ®Google Scholar
• Ettinger AB, LoPresti A, Yang HC, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252–1263. doi:10.1111/epi.1305426140524
   PubMed Web of Science ®Google Scholar
• Leppik IE, Yang HC, Williams B, et al. Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies. Epilepsia. 2017;58(1):51–59. doi:10.1111/epi.1360027869305
   PubMed Web of Science ®Google Scholar
• Rosati A, Ilvento L, Lucenteforte E, et al. Comparative efficacy of antiepileptic drugs in children and adolescents: a network meta-analysis. Epilepsia. 2018;59(2):297–314. doi:10.1111/epi.1398129270989
   PubMed Web of Science ®Google Scholar
• Biro A, Stephani U, Tarallo T, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015;46(2):110-+. doi:10.1055/s-0035-1546276
   Web of Science ®Google Scholar
• De Liso P, Vigevano F, Specchio N, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies an Italian observational multicenter study. Epilepsy Res. 2016;127:93–100. doi:10.1016/j.eplepsyres.2016.08.02127568598
   PubMed Web of Science ®Google Scholar
• Datta AN, Xu Q, Sachedina S, Boelman C, Huh L, Connolly MB. Clinical experience with perampanel for refractory pediatric epilepsy in One Canadian Center. J Child Neurol. 2017;32(9):834–839. doi:10.1177/088307381770919528511603
   PubMed Web of Science ®Google Scholar
• Heyman E, Lahat E, Levin N, et al. Tolerability and efficacy of perampanel in children with refractory epilepsy. Dev Med Child Neurol. 2017;59(4):441–444. doi:10.1111/dmcn.1336227935018
   PubMed Web of Science ®Google Scholar
• Lin KL, Lin JJ, Chou ML, et al. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav. 2018;85:188–194. doi:10.1016/j.yebeh.2018.06.03330032806
   PubMed Web of Science ®Google Scholar
• Swiderska N, Tan HJ, Rajai A, Silwal A, Desurkar A, Martland T. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study. Seizure. 2017;52:63–70. doi:10.1016/j.seizure.2017.08.01428992560
   PubMed Web of Science ®Google Scholar
• Yun Y, Kim D, Lee YJ, Kwon S, Hwang SK. Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy. Korean J Pediatr. 2018;62:269–273.30590000
   PubMedGoogle Scholar
• Kanemura H, Sano F, Aihara M. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy. Eur J Paediatr Neurol. 2019;23(1):197–203. doi:10.1016/j.ejpn.2018.10.00430424990
   PubMed Web of Science ®Google Scholar
• Singh K, Shah YD, Luciano D, Friedman D, Devinsky O, Kothare SV. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study. Epilepsy Behav. 2016;61:41–45. doi:10.1016/j.yebeh.2016.05.00727300147
   PubMed Web of Science ®Google Scholar